看到一堆智障高潮，难怪台湾生医做不起来
请问高端联亚若没有要在美国上市，干嘛去拿美国FDA认证EUA？
台湾是美国第51洲腻？
此外，美国疫苗数量已经够了，当然没有发EUA的理由
但其他国家还是水深火热，疫苗难求好吗
※ 引述《yu0417 (谦)》之铭言：
: 美国FDA宣布除了最后一支Novavax 疫苗可以采用紧急授权机制外，
: 以后将不再发布EUA任何一家疫苗，美国 FDA 可能不会在大流行期间
: 审查新的 COVID-19 疫苗对 EUA 请求。
: 这是不是意味高端联亚在取得美国FDA 认证EUA上将面临新的变量。
: 网址https://reurl.cc/EnRexR
: The U.S. Food and Drug Administration said on Tuesday it may decline to
: review and process new emergency use authorization (EUA) requests for
: COVID-19 vaccines for the rest of the pandemic, if a company has not already
: begun discussions.
: So far, vaccines from Pfizer Inc (PFE.N), Moderna Inc (MRNA.O) and Johnson &
: Johnson (JNJ.N) have been authorized for emergency use in the United States.
: (https://bit.ly/3fOpP2S)
: Novavax Inc (NVAX.O) has had discussions with regulators and said it does not
: expect to seek regulatory authorization for its COVID-19 shot in the United
: States, Britain and Europe until the third quarter of 2021. read more
: Canadian drug developer Medicago said it was in discussions with the FDA for
: an EUA for its plant-based COVID-19 vaccine candidate, which is enhanced by a
: GlaxoSmithKline (GSK.L) treatment.
: AstraZeneca (AZN.L) also has discussed plans for its COVID-19 vaccine with
: U.S. officials. However, the Wall Street Journal earlier this month reported
: that it was considering skipping U.S. emergency-use authorization and instead
: pursue the more time-intensive application for a full-fledged license to sell
: the shot. read more
: AstraZeneca and Novavax did not immediately respond to requests for comment.
: Our Standards: The Thomson Reuters Trust Principles.
: 这是真的吗?